ZA200700433B - Therapeutic composition with a botulinum neurotoxin - Google Patents
Therapeutic composition with a botulinum neurotoxin Download PDFInfo
- Publication number
- ZA200700433B ZA200700433B ZA200700433A ZA200700433A ZA200700433B ZA 200700433 B ZA200700433 B ZA 200700433B ZA 200700433 A ZA200700433 A ZA 200700433A ZA 200700433 A ZA200700433 A ZA 200700433A ZA 200700433 B ZA200700433 B ZA 200700433B
- Authority
- ZA
- South Africa
- Prior art keywords
- botulinum
- neurotoxin
- composition
- aqueous solution
- botulinum neurotoxin
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title claims description 57
- 231100001103 botulinum neurotoxin Toxicity 0.000 title claims description 47
- 239000000203 mixture Substances 0.000 title claims description 47
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 239000002581 neurotoxin Substances 0.000 claims description 39
- 231100000618 neurotoxin Toxicity 0.000 claims description 38
- 101710138657 Neurotoxin Proteins 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 23
- 239000003381 stabilizer Substances 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 15
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 14
- 229920002674 hyaluronan Polymers 0.000 claims description 14
- 229960003160 hyaluronic acid Drugs 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000006174 pH buffer Substances 0.000 claims description 12
- 108010088751 Albumins Proteins 0.000 claims description 10
- 102000009027 Albumins Human genes 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000004071 biological effect Effects 0.000 claims description 7
- 230000000536 complexating effect Effects 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 7
- 238000010353 genetic engineering Methods 0.000 claims description 7
- 230000000087 stabilizing effect Effects 0.000 claims description 7
- 241000193155 Clostridium botulinum Species 0.000 claims description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical group [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 239000002577 cryoprotective agent Substances 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- 208000008035 Back Pain Diseases 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 208000004095 Hemifacial Spasm Diseases 0.000 claims description 4
- 208000008930 Low Back Pain Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 206010005159 blepharospasm Diseases 0.000 claims description 4
- 230000000744 blepharospasm Effects 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 3
- 206010039424 Salivary hypersecretion Diseases 0.000 claims description 3
- 208000008630 Sialorrhea Diseases 0.000 claims description 3
- 206010044074 Torticollis Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- 229960000367 inositol Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 208000018198 spasticity Diseases 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 150000005846 sugar alcohols Polymers 0.000 claims description 3
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 230000037315 hyperhidrosis Effects 0.000 claims description 2
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims description 2
- 208000004350 Strabismus Diseases 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000018197 inherited torticollis Diseases 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 description 11
- 231100000765 toxin Toxicity 0.000 description 11
- 108700012359 toxins Proteins 0.000 description 11
- 238000009472 formulation Methods 0.000 description 8
- 229940053031 botulinum toxin Drugs 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229940089093 botox Drugs 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000036515 potency Effects 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940094657 botulinum toxin type a Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 229940098753 dysport Drugs 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 101000994673 Urodacus yaschenkoi Potassium channel toxin alpha-KTx 6.21 Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000037424 autonomic function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000632 dystonic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- -1 mannito=l Chemical compound 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/86—Products or compounds obtained by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59119604P | 2004-07-26 | 2004-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200700433B true ZA200700433B (en) | 2008-07-30 |
Family
ID=35355516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200700433A ZA200700433B (en) | 2004-07-26 | 2007-01-15 | Therapeutic composition with a botulinum neurotoxin |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US7879341B2 (no) |
| EP (3) | EP1786459B1 (no) |
| JP (3) | JP4907530B2 (no) |
| KR (3) | KR100852821B1 (no) |
| CN (2) | CN101005853B (no) |
| AU (1) | AU2005274822B2 (no) |
| BR (1) | BRPI0513850A (no) |
| CA (2) | CA2578250C (no) |
| EA (1) | EA011652B1 (no) |
| EC (1) | ECSP077197A (no) |
| ES (1) | ES2479515T3 (no) |
| HK (1) | HK1107670A1 (no) |
| IL (3) | IL180771A (no) |
| MX (1) | MX2007000794A (no) |
| NO (1) | NO20071043L (no) |
| WO (1) | WO2006020208A2 (no) |
| ZA (1) | ZA200700433B (no) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| EP2364734B1 (en) * | 2000-07-21 | 2017-09-06 | ReVance Therapeutics, Inc. | Multi-component biological transport systems |
| US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
| US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
| US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| SG10201803560WA (en) * | 2004-03-03 | 2018-06-28 | Revance Therapeutics Inc | Compositions And Methods For Topical Application And Transdermal Delivery Of Botulinum Toxins |
| US8974774B2 (en) * | 2004-03-03 | 2015-03-10 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| KR100852821B1 (ko) * | 2004-07-26 | 2008-08-18 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 신경독소를 포함하는 치료 조성물 |
| ZA200707351B (en) * | 2005-03-03 | 2010-02-24 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
| KR101453963B1 (ko) | 2005-03-03 | 2014-10-22 | 레반스 테라퓨틱스, 아이엔씨. | 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및 방법 |
| CN101384247B (zh) | 2005-07-18 | 2013-05-22 | 麻萨诸塞州洛厄尔大学 | 制备与使用纳米乳剂的组合物和方法 |
| US8137677B2 (en) | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| AU2013202329B2 (en) * | 2005-10-06 | 2016-04-14 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| US8168206B1 (en) * | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
| KR101423272B1 (ko) * | 2005-11-17 | 2014-07-30 | 레반스 테라퓨틱스, 아이엔씨. | 감소된 비-독소 단백질을 갖는 보툴리눔 독소의 국소 적용및 경피 전달을 위한 조성물 및 방법 |
| DK3144013T3 (en) | 2005-12-01 | 2019-03-04 | Univ Massachusetts Lowell | Botulinum nanoemulsions |
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
| US20080063732A1 (en) * | 2006-07-31 | 2008-03-13 | Hantash Basil M | Method of increasing the efficacy of neurotoxin |
| RU2465893C2 (ru) * | 2006-08-02 | 2012-11-10 | Йоханнес Гутенберг-Университет Майнц | Лекарственное средство от отравлений |
| EP2091516A2 (en) | 2006-12-01 | 2009-08-26 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
| MX2009005727A (es) | 2006-12-01 | 2009-08-27 | Anterios Inc | Nanoparticulas de entidad anfifilica. |
| CN101583274A (zh) * | 2006-12-29 | 2009-11-18 | 雷文斯治疗公司 | 使用反向序列hiv-tat多肽的运输分子 |
| CN101616682A (zh) * | 2006-12-29 | 2009-12-30 | 雷文斯治疗公司 | 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法 |
| EP2162117B1 (en) | 2007-05-31 | 2018-02-21 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
| EP2048156A1 (en) * | 2007-10-12 | 2009-04-15 | Merz Pharma GmbH & Co.KGaA | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin |
| CA2686637A1 (en) * | 2007-06-01 | 2008-12-04 | Merz Pharma Gmbh & Co. Kgaa | Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in solid form |
| ES2391798T3 (es) * | 2007-07-10 | 2012-11-30 | Medy-Tox, Inc. | Composición líquida farmacéutica de toxina botulínica con estabilidad mejorada |
| DE102007038015A1 (de) * | 2007-08-10 | 2009-02-19 | Hefter, Harald, Prof. Dr. med. Dr. rer. nat. | Verwendung eines Neurotoxins |
| PL2198007T3 (pl) | 2007-09-14 | 2018-03-30 | Sanofi Pasteur Biologics, Llc | Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile |
| US9044477B2 (en) | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
| US9161970B2 (en) * | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
| EP2072039A1 (en) * | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects |
| US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| KR20090124421A (ko) | 2008-05-30 | 2009-12-03 | 현대자동차주식회사 | 자동 변속기용 주차 브레이크 장치 |
| EP3650017A1 (en) * | 2008-06-26 | 2020-05-13 | Anterios, Inc. | Dermal delivery |
| EP2373294B1 (en) * | 2008-12-10 | 2016-04-20 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| CN102300584A (zh) | 2008-12-31 | 2011-12-28 | 雷文斯治疗公司 | 可注射的肉毒杆菌毒素制剂 |
| ES2538835T3 (es) | 2009-01-07 | 2015-06-24 | Robert John Petrella | Tratamiento de lesiones de tejidos blandos utilizando el ácido hialurónico y la toxina botulínica |
| MX340772B (es) * | 2009-02-19 | 2016-07-26 | Merz Pharma Gmbh & Co Kgaa | Medios y metodos para fabricar neurotoxina altamente pura. |
| EP2248518B1 (en) * | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| IL268980B (en) | 2009-06-25 | 2022-09-01 | Revance Therapeutics Inc | Botulinum toxin formulations without albumin |
| BRPI1014253A2 (pt) | 2009-07-02 | 2016-04-12 | Merz Pharma Gmbh & Co Kgaa | polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento |
| US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| RU2013119297A (ru) * | 2010-10-06 | 2014-11-20 | Аллерган, Инк. | Система для хранения и последующей обработки ботулотоксина |
| AU2011316111B2 (en) | 2010-10-12 | 2015-05-28 | Merz Pharma Gmbh & Co. Kgaa | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
| US20120195878A1 (en) * | 2011-01-28 | 2012-08-02 | Allergan, Inc. | Protocol for the administration of botulinum toxins |
| MX351012B (es) | 2011-11-09 | 2017-09-28 | Merz Pharma Gmbh & Co Kgaa | Neurotoxinas que exhiben actividad biologica acortada. |
| US10980865B2 (en) * | 2012-08-10 | 2021-04-20 | Aquavit Pharmaceuticals, Inc. | Direct application system and method for the delivery of bioactive compositions and formulations |
| US10894062B2 (en) | 2012-08-10 | 2021-01-19 | Aquavit Pharmaceuticals, Inc. | Vitamin supplement compositions for injection |
| CA2889833A1 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
| JP2016513082A (ja) | 2013-01-28 | 2016-05-12 | ニューヨーク・ユニバーシティ | 無毒性神経毒誘導体を用いる治療方法 |
| KR20140147950A (ko) * | 2013-06-20 | 2014-12-31 | 서울대학교산학협력단 | 필러와 보틀리눔 독소를 포함하는 피부 주름, 노화 개선 또는 신경근육 관련 질환 치료용 조성물 |
| MX360513B (es) | 2013-06-28 | 2018-11-07 | Merz Pharma Gmbh & Co Kgaa | Medios y metodos para la determinacion de la actividad biologica de polipeptidos de neurotoxina en celulas. |
| KR101339349B1 (ko) * | 2013-08-02 | 2013-12-09 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| WO2015024503A1 (en) * | 2013-08-21 | 2015-02-26 | The Hong Kong Polytechnic University | Engineering clostridia neurotoxins with elevated catalytic activity |
| US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| CA2969463A1 (en) | 2014-12-09 | 2016-06-16 | New York University | Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use |
| EP3233911B1 (en) | 2014-12-19 | 2020-10-14 | Merz Pharma GmbH & Co. KGaA | Means and methods for the determination of the biological activity of bont/e in cells |
| MX2018008855A (es) | 2016-03-02 | 2018-11-29 | Merz Pharma Gmbh & Co Kgaa | Composicion que comprende toxina botulinica. |
| WO2017188618A1 (en) * | 2016-04-26 | 2017-11-02 | Korea Prime Pharm Co., Ltd. | A novel composition comprising botulinum toxin |
| DK3679946T3 (da) * | 2016-05-27 | 2022-02-07 | Ipsen Biopharm Ltd | Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin |
| WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
| EP3290437A1 (en) | 2016-08-31 | 2018-03-07 | Merz Pharma GmbH & Co. KGaA | Novel recombinant clostridial neurotoxins with decreased duration of effect |
| BR112019004929A2 (pt) | 2016-09-13 | 2019-06-04 | Allergan Inc | composições de toxina clostridial não proteíca |
| EP3312193A1 (en) | 2016-10-19 | 2018-04-25 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with accelerated onset of effect |
| BR112019010131A2 (pt) | 2016-11-21 | 2019-10-08 | Eirion Therapeutics Inc | entrega transdérmica de agentes grandes |
| EP3333179A1 (en) | 2016-12-07 | 2018-06-13 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with accelarated onset of effect |
| EP3335719A1 (en) | 2016-12-14 | 2018-06-20 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with a stabilized light chain |
| BR112019016585A2 (pt) | 2017-03-24 | 2020-03-31 | Merz Pharma Gmbh & Co. Kgaa | Uso melhorado da neurotoxina botulínica no tratamento da sialorreia |
| US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
| WO2019005773A1 (en) * | 2017-06-26 | 2019-01-03 | Bonti, Inc. | CLOSTRIDIAL NEUROTOXIN FORMULATIONS AND USE |
| EP3649143B1 (en) | 2017-07-06 | 2022-08-31 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
| KR20190038292A (ko) | 2017-09-29 | 2019-04-08 | 한국프라임제약주식회사 | 효능 지속시간이 연장된 보툴리눔 독소 조성물 |
| EP3700919A1 (en) | 2017-10-26 | 2020-09-02 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
| US20200354706A1 (en) | 2017-11-22 | 2020-11-12 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
| KR102274232B1 (ko) | 2018-08-28 | 2021-07-08 | 성균관대학교산학협력단 | 신경세포 표적용 단백질 조성물 |
| GB201815844D0 (en) * | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
| EP3860640A1 (en) | 2018-10-02 | 2021-08-11 | Merz Pharma GmbH & Co. KGaA | Novel uses of botulinum neurotoxin for treating lipoedema |
| MX2021009922A (es) | 2019-02-21 | 2021-09-14 | Merz Pharma Gmbh & Co Kgaa | Usos novedosos de neurotoxina botulinica para el tratamiento del temblor. |
| US11202753B1 (en) | 2020-03-06 | 2021-12-21 | Aquavit Pharmaceuticals, Inc. | Systems and methods for generating immune responses in subjects using microchannel delivery devices |
| US20230329996A1 (en) | 2020-06-05 | 2023-10-19 | Merz Pharma Gmbh & Co. Kgaa | High dose and low volume botulinum toxin treatment of facial wrinkles |
| JP2024522930A (ja) | 2021-07-05 | 2024-06-21 | ファルマ リサーチ バイオ シーオー・，エルティーディー． | クロストリジウム・ボツリヌス毒素複合体タンパク質の精製方法 |
| JP2024522931A (ja) | 2021-07-08 | 2024-06-21 | ファルマ リサーチ バイオ シーオー・，エルティーディー． | 非毒素タンパク質が除去されたクロストリジウム・ボツリヌス神経毒素タンパク質の精製方法 |
| WO2023085849A1 (ko) | 2021-11-15 | 2023-05-19 | (주)메디톡스 | 보툴리눔 독소 조성물 |
| TW202400122A (zh) | 2022-02-28 | 2024-01-01 | 德商梅茲製藥有限兩合公司 | 肉毒桿菌毒素用於降低皮膚毛孔尺寸及／或皮脂產生之用途、以及降低皮膚毛孔尺寸及／或皮脂產生的方法 |
| CN115040641B (zh) * | 2022-06-29 | 2024-10-29 | 无锡市太湖医院 | 神经外科术前干预药物组合物 |
| KR102551301B1 (ko) | 2022-10-28 | 2023-07-03 | 주식회사 파마리서치바이오 | 보툴리눔 독소를 포함하는 안정한 액상 제제 |
| WO2024115413A1 (en) | 2022-11-28 | 2024-06-06 | Merz Pharma Gmbh & Co. Kgaa | High concentration botulinum toxin treatment for neck rejuvenation |
| WO2024115412A1 (en) | 2022-11-28 | 2024-06-06 | Merz Pharma Gmbh & Co. Kgaa | Botulinum toxin injection in platysma for lower face and neck rejuvenation |
| WO2024194181A1 (en) | 2023-03-20 | 2024-09-26 | Merz Therapeutics GmbH | Nh3 scavenger for use in the treatment of mobility disability in a post-stroke patient |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZW14486A1 (en) | 1985-07-29 | 1986-10-22 | Smithkline Beckman Corp | Pharmaceutical dosage unit |
| GB8816443D0 (en) * | 1988-07-11 | 1988-08-17 | Albright & Wilson | Liquid enzymatic detergents |
| US5215743A (en) * | 1988-04-13 | 1993-06-01 | Maninder Singh | Tumor necrosis factor formulations |
| JPH03479A (ja) | 1989-05-25 | 1991-01-07 | Hitachi Ltd | プラズマ溶接装置及び溶接方法 |
| JPH034791A (ja) | 1989-05-30 | 1991-01-10 | Kanebo Ltd | 酵素の安定化方法 |
| JP3504721B2 (ja) | 1994-05-09 | 2004-03-08 | エアバックス インターナショナル リミティド | 袋織エアバッグ |
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| EP0817613B1 (en) * | 1996-01-31 | 2005-03-30 | Cosmoferm B.V. | Use of compositions comprising stabilized enzymes |
| US20120238504A1 (en) * | 1998-09-11 | 2012-09-20 | Solstice Neurosciences, Llc | Stable Formulations of Botulinum Toxin in Hydrogels |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| ES2275992T5 (es) * | 2000-02-08 | 2011-05-18 | Allergan, Inc. | Composiciones farmacéuticas de toxina botulínica. |
| US8632785B2 (en) * | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
| US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| JP4711520B2 (ja) * | 2000-03-21 | 2011-06-29 | 日本ケミカルリサーチ株式会社 | 生理活性ペプチド含有粉末 |
| US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| US6645526B2 (en) * | 2001-11-13 | 2003-11-11 | Mylan Pharmaceuticals, Inc. | Storage stable thyroxine active drug formulations and methods for their production |
| US7820194B2 (en) * | 2001-12-21 | 2010-10-26 | Alcon, Inc. | Combinations of viscoelastics for use during surgery |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| SI21257A (sl) * | 2002-07-17 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Stabilni farmacevtski pripravek, ki vsebuje eritropoietin |
| EP1594523B1 (en) * | 2002-12-20 | 2009-03-25 | Botulinum Toxin Research Associates, Inc. | Pharmaceutical compositions comprising botulinum toxin and human serum albumin |
| KR100852821B1 (ko) * | 2004-07-26 | 2008-08-18 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 신경독소를 포함하는 치료 조성물 |
| US8926991B2 (en) * | 2005-06-14 | 2015-01-06 | Botulinum Toxin Research Associates, Inc. | Botulinum toxin and the treatment of primary disorders of mood and affect |
| US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| WO2007044809A2 (en) * | 2005-10-11 | 2007-04-19 | Botulinum Toxin Research Associates, Inc. | Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use |
| US20070154493A1 (en) * | 2005-12-30 | 2007-07-05 | Judy Hattendorf | Method of treating skin needing botulinum toxin type a treatment |
| MX340772B (es) * | 2009-02-19 | 2016-07-26 | Merz Pharma Gmbh & Co Kgaa | Medios y metodos para fabricar neurotoxina altamente pura. |
| EP2248518B1 (en) * | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| IL268980B (en) * | 2009-06-25 | 2022-09-01 | Revance Therapeutics Inc | Botulinum toxin formulations without albumin |
| CN102597769B (zh) * | 2009-10-21 | 2014-11-05 | 莫茨制药有限及两合公司 | 用于测定未加工和部分加工的神经毒素a多肽的系统 |
| SI2526200T1 (sl) * | 2010-01-22 | 2016-07-29 | Merz Pharma Gmbh & Co. Kgaa | In vitro preizkus za kvanitificiranje aktivnosti klostridijskega nevrotoksina |
| WO2011103465A2 (en) * | 2010-02-20 | 2011-08-25 | Alexey Gennadievich Zdanovsky | Botulinum neurotoxin antigenic compositions and methods |
| US20120201857A1 (en) * | 2010-03-17 | 2012-08-09 | Pankaj Modi | Transdermal delivery system for therapeutics |
| AU2011316111B2 (en) * | 2010-10-12 | 2015-05-28 | Merz Pharma Gmbh & Co. Kgaa | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
| KR101395064B1 (ko) * | 2011-03-31 | 2014-05-19 | (주)메디톡스 | 보톨리눔 독소의 동결건조제제 |
| EP2694975A1 (en) * | 2011-04-08 | 2014-02-12 | Biogen Idec MA Inc. | Biomarkers predictive of therapeutic responsiveness to ifnbeta and uses thereof |
| JP6236332B2 (ja) | 2014-02-24 | 2017-11-22 | ホシザキ株式会社 | 冷温蔵装置 |
-
2005
- 2005-07-19 KR KR1020087012496A patent/KR100852821B1/ko active IP Right Grant
- 2005-07-19 EP EP05765454.3A patent/EP1786459B1/en active Active
- 2005-07-19 EP EP10181506.6A patent/EP2266599B1/en active Active
- 2005-07-19 JP JP2007523628A patent/JP4907530B2/ja active Active
- 2005-07-19 CA CA2578250A patent/CA2578250C/en not_active Expired - Fee Related
- 2005-07-19 KR KR1020077001912A patent/KR100852822B1/ko active IP Right Grant
- 2005-07-19 CN CN2005800282064A patent/CN101005853B/zh active Active
- 2005-07-19 ES ES10181506.6T patent/ES2479515T3/es active Active
- 2005-07-19 AU AU2005274822A patent/AU2005274822B2/en active Active
- 2005-07-19 KR KR1020087012497A patent/KR100852824B1/ko active IP Right Grant
- 2005-07-19 CN CN2011100729910A patent/CN102139099A/zh active Pending
- 2005-07-19 EA EA200700213A patent/EA011652B1/ru not_active IP Right Cessation
- 2005-07-19 CA CA2799413A patent/CA2799413A1/en not_active Abandoned
- 2005-07-19 US US11/184,495 patent/US7879341B2/en active Active
- 2005-07-19 MX MX2007000794A patent/MX2007000794A/es active IP Right Grant
- 2005-07-19 WO PCT/US2005/025408 patent/WO2006020208A2/en active Application Filing
- 2005-07-19 BR BRPI0513850-7A patent/BRPI0513850A/pt not_active Application Discontinuation
- 2005-07-19 EP EP10184484.3A patent/EP2266600B1/en active Active
-
2007
- 2007-01-15 ZA ZA200700433A patent/ZA200700433B/en unknown
- 2007-01-17 IL IL180771A patent/IL180771A/en not_active IP Right Cessation
- 2007-01-25 EC EC2007007197A patent/ECSP077197A/es unknown
- 2007-02-23 NO NO20071043A patent/NO20071043L/no not_active Application Discontinuation
- 2007-12-05 HK HK07113262.7A patent/HK1107670A1/xx unknown
-
2010
- 2010-10-15 JP JP2010232458A patent/JP2011016846A/ja active Pending
- 2010-12-22 US US12/928,898 patent/US8372645B2/en active Active
-
2012
- 2012-05-20 IL IL219897A patent/IL219897A0/en unknown
-
2013
- 2013-01-10 US US13/738,283 patent/US8652489B2/en active Active
- 2013-03-07 JP JP2013045137A patent/JP2013107904A/ja not_active Withdrawn
- 2013-04-18 IL IL225848A patent/IL225848A0/en unknown
- 2013-12-19 US US14/134,505 patent/US9050367B2/en active Active
-
2015
- 2015-05-05 US US14/704,320 patent/US9220783B2/en active Active
- 2015-11-24 US US14/950,587 patent/US10105421B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200700433B (en) | Therapeutic composition with a botulinum neurotoxin | |
| JP6235176B2 (ja) | 非タンパク質安定化クロストリジウム毒素医薬組成物 | |
| JP2004256545A (ja) | ボツリヌス毒素医薬組成物 | |
| CN101175478A (zh) | 非蛋白稳定的梭菌毒素药物组合物 | |
| BRPI0613001B1 (pt) | Composições farmacêuticas de toxina clostrídica estabilizada por uma não-proteína |